An antimicrobial peptide with high antimicrobial activity, an antimicrobial composition, a preparation method and applications
By constructing an antimicrobial peptide training dataset and using artificial intelligence for design, antimicrobial peptides were synthesized using a solid-phase chemical method. This solved the problems of low activity, high toxicity, and high purification cost of antimicrobial peptides in existing technologies, achieving efficient, low-cost, broad-spectrum antimicrobial activity and low toxicity.
Patent Information
- Application Number
- CN202611162739.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-03
- Publication Date
- 2026-11-17
AI Technical Summary
Existing antimicrobial peptides have low activity and high toxicity, are easily degraded during production, have high purification costs, and are difficult to effectively combat multidrug-resistant bacteria.
By constructing an antimicrobial peptide training dataset, artificial intelligence was used to design and synthesize antimicrobial peptides with broad spectrum, high bioactivity, and low toxicity. These peptides were then synthesized using solid-phase chemical methods and purified to a purity of over 95% to prepare antimicrobial compositions.
It has achieved efficient and low-cost synthesis of antimicrobial peptides with broad-spectrum antibacterial activity and low toxicity, especially with significant inhibitory effects on Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, with high safety and purity.
Smart Images

Figure CN123106833A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of antimicrobial drug technology, specifically relating to an antimicrobial peptide with high antimicrobial activity, an antimicrobial composition, a preparation method, and its application. Background Technology
[0002] Antibiotic resistance has become a major challenge in modern medicine. In recent decades, the number of drug-resistant pathogens has continued to rise, with multidrug-resistant and even superdrug-resistant bacteria emerging, widely recognized as a serious threat to global public health. Against the backdrop of ongoing efforts to replace antibiotics, antimicrobial peptides have emerged as important candidates for combating drug-resistant infections due to their unique mechanisms of action. Antimicrobial peptides are short peptides with antimicrobial activity, offering advantages such as low resistance induction, rapid onset of action, and easy degradation, without causing persistent environmental pollution. Their bactericidal mechanisms are diverse, the most common being binding to the cell membrane of pathogenic microorganisms and disrupting its structure, or directly creating pores in the membrane leading to leakage of intracellular substances, thereby killing the pathogens. In recent years, antimicrobial peptides that are effective against multidrug-resistant bacteria and less likely to induce resistance have been widely regarded as ideal alternatives to next-generation antimicrobial drugs.
[0003] Antimicrobial activity is typically measured by the minimum inhibitory concentration (MIC). A high MIC requires large doses to be effective, rendering such products impractical. Furthermore, high concentrations can lead to safety risks such as cytotoxicity and hemolysis. Currently reported antimicrobial peptides generally suffer from low activity and high toxicity. In terms of preparation, existing methods mainly include natural extraction, enzymatic hydrolysis, genetic engineering, and microbial fermentation. However, as bioactive polypeptides, antimicrobial peptides are often degraded by host bacteria during fermentation, leading to their consumption during production and loss of utilization value. Whether naturally derived or obtained through genetic engineering, antimicrobial peptides are present in very low concentrations in purification systems, often mixed with large amounts of impurities such as proteins and other components, resulting in high purification costs. Summary of the Invention
[0004] The technical problem solved by this invention is to provide an antimicrobial peptide with high antibacterial activity, an antimicrobial composition, a preparation method, and applications. This antimicrobial peptide has advantages such as broad-spectrum activity, high bioactivity, low toxicity, and low hemolytic activity. The antimicrobial peptide has a short synthetic sequence and small molecular weight, making it easy to synthesize chemically. It is synthesized using a solid-phase chemical method, which results in good stability, high purity, and low synthesis cost.
[0005] To address the above problems, a first aspect of the present invention provides an antimicrobial peptide with high antimicrobial activity, the amino acid sequence of which is shown in SEQ ID NO: 1.
[0006] A second aspect of the present invention provides an antibacterial composition comprising the above-described antibacterial peptide with high antibacterial activity.
[0007] Preferably, it also includes pharmaceutically acceptable pharmaceutical excipients.
[0008] A third aspect of the present invention provides a method for preparing the above-mentioned antimicrobial peptide with high antimicrobial activity, comprising the following steps: Using a solid-phase synthesis method, the antimicrobial peptide is sequentially condensed from the C-terminus to the N-terminus to complete the peptide chain, based on the amino acid sequence of the antimicrobial peptide, to obtain the antimicrobial peptide with high antimicrobial activity.
[0009] Preferably, the method further includes removing the peptide from the resin with a cleavage fluid after condensation to the peptide chain, and removing the side chain protecting groups.
[0010] Preferably, the process further includes precipitating the crude polypeptide with ice-cold ether after removing the polypeptide from the resin and removing the side chain protecting groups, then purifying the crude polypeptide to a purity of over 95% using a preparative high-performance liquid chromatography (HPLC) instrument, and then freeze-drying it.
[0011] A fourth aspect of the present invention provides the use of the above-mentioned antimicrobial peptide with high antimicrobial activity in the preparation of a medicament for the prevention or treatment of bacterial infections.
[0012] Preferably, the bacteria are one or more of Gram-negative and Gram-positive bacteria.
[0013] Preferably, the Gram-negative bacteria are one or more of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The Gram-positive bacteria is Staphylococcus aureus.
[0014] Preferably, the bacteria are one or more of Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
[0015] Compared with the prior art, the present invention has the following advantages: This invention utilizes publicly available databases UniProt, LAMP2.0, DBAASP, DRAMP, dbAMP, satPDB, and GRAMPA to construct an antimicrobial peptide training dataset for large-scale pre-training. After training, with a fixed target conditional vector, an antimicrobial peptide with simple structure, broad spectrum, high bioactivity, low toxicity, and low hemolytic activity was designed and developed using artificial intelligence. This antimicrobial peptide has a short synthetic sequence, small molecular weight, and is easy to synthesize chemically using a solid-phase chemical method. The synthesis process exhibits good stability, high purity, and low cost. This antimicrobial peptide shows significant inhibitory effects, particularly against Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
[0016] The antimicrobial peptide of the present invention is synthesized by solid-phase chemical method, which has a short synthesis sequence, small molecular weight, and is easy to synthesize chemically. The synthesis process by solid-phase chemical method has good stability, high purity, and low synthesis cost. Attached Figure Description
[0017] Figure 1 This is a graph showing the cytotoxicity test results of the antimicrobial peptide in Example 4 of this invention; Figure 2 This is a graph showing the hemolytic effect of the antimicrobial peptide in Example 5 of this invention. Detailed Implementation
[0018] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0019] A first aspect of the present invention provides an antimicrobial peptide with high antimicrobial activity, the amino acid sequence of which is shown in SEQ ID NO: 1.
[0020] SEQ ID NO: 1: KKWKRWKKLLKKIL.
[0021] This invention utilizes publicly available databases UniProt, LAMP2.0, DBAASP, DRAMP, dbAMP, satPDB, and GRAMPA to construct an antimicrobial peptide training dataset for large-scale pre-training. After training, with a fixed target conditional vector, a broad-spectrum antimicrobial peptide with simple structure, broad-spectrum activity, high bioactivity, low toxicity, and low hemolytic activity was designed and developed through artificial intelligence. This broad-spectrum antimicrobial peptide has a short synthetic sequence, small molecular weight, and is easy to synthesize chemically using a solid-phase chemical method. The synthesis process exhibits good stability, high purity, and low synthesis cost. This antimicrobial peptide shows significant inhibitory effects, particularly against Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
[0022] A second aspect of the present invention provides an antibacterial composition comprising the above-mentioned antibacterial peptide with high antibacterial activity.
[0023] Preferably, it also includes pharmaceutically acceptable pharmaceutical excipients.
[0024] A third aspect of the present invention provides a method for preparing the above-mentioned antimicrobial peptide with high antimicrobial activity, comprising the following steps: Using a solid-phase synthesis method, the antimicrobial peptide is sequentially condensed from the C-terminus to the N-terminus to complete the peptide chain, based on the amino acid sequence of the antimicrobial peptide, to obtain the antimicrobial peptide with high antimicrobial activity.
[0025] The broad-spectrum antimicrobial peptides of this invention have short synthetic sequences and small molecular weights, making them easy to synthesize chemically. They are synthesized using solid-phase chemical methods, resulting in good stability, high purity, and low synthesis cost.
[0026] Preferably, the method further includes removing the peptide from the resin with a cleavage fluid after condensation to the peptide chain, and removing the side chain protecting groups.
[0027] Preferably, the process further includes precipitating the crude polypeptide with ice-cold ether after removing the polypeptide from the resin and removing the side chain protecting groups, then purifying the crude polypeptide to a purity of over 95% using a preparative high-performance liquid chromatography (HPLC) instrument, and then freeze-drying it.
[0028] A fourth aspect of the present invention provides the use of the above-mentioned antimicrobial peptide with high antimicrobial activity in the preparation of a medicament for the prevention or treatment of bacterial infections.
[0029] Preferably, the bacteria are one or more of Gram-negative and Gram-positive bacteria.
[0030] Preferably, the Gram-negative bacteria are one or more of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The Gram-positive bacteria is Staphylococcus aureus.
[0031] Preferably, the bacteria are one or more of Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
[0032] Example 1: Design of Antimicrobial Peptides A multi-attribute antimicrobial peptide training dataset was constructed using the publicly available databases UniProt, LAMP2.0, DBAASP, DRAMP, dbAMP, satPDB, and GRAMPA. First, 25,885 peptide sequences with antimicrobial activity were collected from LAMP2.0, DBAASP, and DRAMP, and 58,776 non-antimicrobial peptide sequences were screened from UniProt. To determine broad-spectrum activity, 11,765 broad-spectrum antimicrobial peptide sequences and 2,594 non-broad-spectrum antimicrobial peptide sequences were further collected from DBAASP and dbAMP. To determine cytotoxicity, 17,659 non-toxic peptides and 8,351 toxic peptides were collected from satPDB and DBAASP. To investigate the inhibitory effect on Staphylococcus aureus, 1,790 positive samples and 6,402 negative samples with Staphylococcus aureus MIC information were collected from the GRAMPA dataset. Among them, the positive samples with quantitative MIC values were also used for subsequent MIC regression tasks.
[0033] In terms of model design, a multi-condition end-to-end generation framework, MGE-AMP, for de novo design of broad-spectrum antimicrobial peptides was constructed. This method uses a Transformer Decoder as its main structure. First, it undergoes large-scale pre-training on approximately 24 million peptide-like sequences shorter than 100 amino acids in UniProt to learn the general distribution patterns and implicit modes of short peptide sequences. Then, supervised fine-tuning is performed based on the processed multi-attribute labeled data. During the fine-tuning stage, MGE-AMP uniformly encodes antimicrobial activity, broad-spectrum activity, non-toxicity, binary MIC labels, and continuous MIC values into conditional vectors. This conditional information is injected into the sequence generation process through a gated cross-attention mechanism, learning biological characteristics closely related to antimicrobial peptide design, such as antimicrobial activity, broad-spectrum activity, non-toxicity, and MIC potency, thereby achieving multi-conditional controllable generation. Simultaneously, the model utilizes shared sequence representations, using classification and regression heads to jointly predict antimicrobial activity, broad-spectrum activity, non-toxicity, binary MIC classification, and continuous MIC values, thus achieving end-to-end modeling of "generation-discrimination-sorting" within the same framework. To address the issue of incomplete multi-attribute labels, a conditional data alignment and enhancement strategy was further designed, enabling the effective utilization of some labeled samples and improving the efficiency of training data utilization.
[0034] After model training is complete, the target condition vector is fixed as antibacterial activity positive, broad-spectrum positive, non-toxicity positive, and MIC positive, and a low target MIC value is set. This allows for the batch generation of candidate peptide sequences that meet the target attribute constraints. For the generated candidate sequences, the multi-task prediction head within the model is first used for re-scoring to screen sequences that simultaneously meet the requirements of antibacterial activity, broad-spectrum activity, non-toxicity, and MIC. Then, the candidate sequences are ranked based on the continuous MIC regression results, thereby selecting the antibacterial peptide sequences with higher potential for experimental validation.
[0035] The antimicrobial peptide sequence is shown in SEQ ID NO: 1: SEQ ID NO: 1: KKWKRWKKLLKKIL.
[0036] The physicochemical properties of this antimicrobial peptide are as follows: Table 1 Physicochemical properties of antimicrobial peptides
[0037] Example 2 Synthesis of antimicrobial peptides The antimicrobial peptides were synthesized using a chemical organic solid-phase synthesis method. The sequence was condensed sequentially from the C-terminus to the N-terminus to complete the peptide chain. The peptides were then excised from the resin using a cleavage fluid, along with the side chain protecting groups. The crude peptides were precipitated with ice-cold ether and purified to a purity of over 95% using a preparative high-performance liquid chromatography (HPLC) system before being lyophilized.
[0038] Example 3: Determination of the activity of antimicrobial peptides Determination of minimum inhibitory concentration of standard strain Bacteria: *Escherichia coli* (ATCC 25922), *Klebsiella pneumoniae* (ATCC 43816), *Acinetobacter baumannii* (ATCC 19606), *Pseudomonas aeruginosa* (ATCC 27853), and *Staphylococcus aureus* (ATCC 25923) were streaked onto LB agar and incubated upside down in a CO2 incubator at 37°C for 24 h. After single colonies formed on the plates, single colonies were picked and transferred to LB liquid medium and incubated at 37°C. Incubate in a shaking incubator for 4 hours until OD reaches 100%. 600 When the concentration is 0.35, dilute the bacterial culture into CAMHB liquid medium and adjust the bacterial count to 10. 5 CFU / mL, keep for later use.
[0039] Dissolve 1 mg of antimicrobial peptide in 1 mL of physiological saline to a concentration of 1 mg / mL. Add 100... Add L of the antimicrobial peptide in a two-fold serial dilution to a 96-well plate, then add 100 L concentration is 10 5 The bacterial suspension contained CFU / mL. At this point, the concentration of the antimicrobial peptide was 500... g / mL, 250 g / mL, 125 g / mL, 62.5 g / mL, 31.25 g / mL, 15.63 g / mL, 7.81 g / mL, 3.91 g / mL and 1.95 g / mL. Record the OD at this time. 600 100 L bacterial solution and 100 L of physiological saline mixture was used as a negative control. The 96-well plate was placed at 37°C. Incubate in a CO2 incubator for 20 h, and record OD again. 600 The minimum inhibitory concentration (MIC) is the lowest concentration at which the growth of a bacterial strain is completely inhibited.
[0040] Antimicrobial peptide antibacterial rate =
[0041] Table 2 shows that the antimicrobial peptides of this invention have significant inhibitory effects on bacteria: Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The minimum inhibitory concentration against Escherichia coli is 250 mg / L. The minimum inhibitory concentration (MIC) against Klebsiella pneumoniae is 3.91 g / mL. The minimum inhibitory concentration (MIC) against Acinetobacter baumannii is 1.95 g / mL. The minimum inhibitory concentration (MIC) against Pseudomonas aeruginosa is 7.81 g / mL. The minimum inhibitory concentration (MIC) against Staphylococcus aureus is 250 g / mL. g / mL. It is evident that the antimicrobial peptides of this invention exhibit particularly significant antibacterial activity against Acinetobacter baumannii.
[0042] Table 2. Minimum inhibitory concentrations of antimicrobial peptides against standard strains
[0043] Example 4: Cytotoxicity assay of antimicrobial peptides Configure 100 in a 96-well plate L cell suspension (10 cells per well) 4 The culture plates were pre-cultured in an incubator for 24 hours (at 37 ℃ and 5% CO2). 100 mg of [unspecified substance] was added to the culture plates. L concentration ranges are 100 and 200 respectively. Add g / mL of the test peptide. Incubate in an incubator for 24 hours. Add 10 g / mL to each well. L CCK-8 solution. Incubate the culture plate in an incubator for 4 hours. Measure the absorbance at 450 nm using a microplate reader.
[0044]
[0045] A (Drug Addition): Absorbance of the well containing cells, CCK-8 solution, and drug solution. A (Blank): Absorbance of wells containing culture medium and CCK-8 solution but without cells. A (0 drug added): Absorbance of the well containing cells and CCK-8 solution but no drug solution. Cell viability: cell proliferation activity or cytotoxic activity Cytotoxicity assays are widely used experimental methods in biological research to assess the toxicity of compounds to cells in vivo. This assay aims to reveal whether the antimicrobial peptides of this invention affect cell structure and function, thereby assessing the potential risks of the antimicrobial peptides to the health of organisms and providing important data for drug development and safety evaluation.
[0046] Depend on Figure 1 The results show that the antimicrobial peptide of the present invention has a 100% efficacy. The cell viability at g / mL is higher than 50%, meaning that the cell proliferation activity is 50% at this concentration. This is significantly different from its MIC value, making it suitable for a wider range of clinical applications.
[0047] Example 5: Hemolytic activity assay of antimicrobial peptides Take a 96-well plate and add 100... L concentration ranges are 100 and 200 respectively. g / mL of the test peptide. Take 100 g / mL of 2% red blood cells. Add the drug solution to a 96-well plate and mix well. Incubate at 37°C for 1 hour, then centrifuge at 5000 rpm for 5 minutes; carefully aspirate 100 ml of the supernatant. Four parallel control wells were set up in the ELISA reader. The negative control was physiological saline, and the positive control was 10% Triton-saline. Physiological saline was chosen as the negative control, and Triton X-100 as the positive control. The results met the experimental requirements: Triton X-100 (positive control) increases cell membrane permeability, causing the system to become isotonic, leading to red blood cell rupture and hemolysis, resulting in a clear red solution. In contrast, no hemolysis or red blood cell agglutination occurred in the physiological saline control tubes (negative control tubes). After comparing each well with the negative and positive control tubes, all red blood cells in all wells sank, the supernatant was colorless and clear, no hemolysis occurred, and the precipitated red blood cells dispersed after shaking without agglutination. The hemolysis rate of the peptide was calculated by measuring the absorbance of the supernatant at OD570nm using an ELISA reader.
[0048]
[0049] Hemolysis refers to reactions such as extravascular or intravascular hemolysis and erythrocyte aggregation caused by drug formulations. This experiment aims to investigate whether the antimicrobial peptide of this invention can induce reactions such as hemolysis and erythrocyte aggregation in vitro. The active ingredient and its metabolites, excipients, related substances, and physicochemical properties (such as pH value, osmotic pressure, etc.) of a drug can all potentially cause hemolysis. Severe toxicity can affect the safety and efficacy of medication. Therefore, before clinical application, the local and / or systemic toxicity caused by the formulation after administration should be studied to indicate potential toxic reactions, target organs of toxicity, safety margins, clinical research monitoring indicators, and to provide a reference for clinical detoxification or rescue measures, ensuring the safety and efficacy of clinical drug use.
[0050] Depend on Figure 2 The results show that the antimicrobial peptide of the present invention has a 200 g / mL and 100 The hemolysis rate of g / mL is less than 5%, which is significantly different from its MIC value, and has a wide range of clinical applications.
[0051] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. An antibacterial peptide having high antibacterial activity, characterized by comprising a sequence represented by SEQ ID NO: 1 or 2. The amino acid sequence of the antimicrobial peptide is shown in SEQ ID NO:
1.
2. An antibacterial composition, characterized by, Includes the antimicrobial peptides with high antimicrobial activity as described in claim 1.
3. The antimicrobial composition according to claim 2, wherein It also includes pharmaceutically acceptable excipients.
4. A method for preparing an antimicrobial peptide with high antimicrobial activity as described in claim 1, characterized in that, Includes the following steps: Using a solid-phase synthesis method, the antimicrobial peptide is sequentially condensed from the C-terminus to the N-terminus to complete the peptide chain, based on the amino acid sequence of the antimicrobial peptide, to obtain the antimicrobial peptide with high antimicrobial activity.
5. The preparation method according to claim 4, characterized in that: It also includes removing the peptide from the resin with a cutting fluid after condensation to the peptide chain, and removing the side chain protecting groups.
6. The preparation method according to claim 5, characterized in that: The process also includes removing the peptide from the resin and removing the side chain protecting groups, precipitating the crude peptide with ice-cold ether, purifying the crude peptide to a purity of over 95% using a preparative high-performance liquid chromatography (HPLC), and then lyophilizing it.
7. The use of an antimicrobial peptide with high antimicrobial activity as described in claim 1 in the preparation of a medicament for the prevention or treatment of bacterial infections.
8. The application according to claim 7, characterized in that: The bacteria are one or more of Gram-negative and Gram-positive bacteria.
9. The application according to claim 8, characterized in that: The Gram-negative bacteria are one or more of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa. The Gram-positive bacteria is Staphylococcus aureus.
10. The application according to claim 8, characterized in that: The bacteria are one or more of Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
